Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase NA 3Phase 3 3Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Breast Neoplasms 298Carcinoma, Non-Small-Cell Lung 226Neoplasms 155Prostatic Neoplasms 154Multiple Myeloma 116Neoplasm Metastasis 83Colorectal Neoplasms 80Leukemia, Myeloid, Acute 74Lung Neoplasms 71Parkinson Disease 4, Autosomal Dominant Lewy Body 68Melanoma 67Leukemia, Lymphocytic, Chronic, B-Cell 63Lymphoma, Follicular 62Lymphoma, Non-Hodgkin 61Papillomavirus Infections 59Leukemia 59Pain 52Lymphoma 52Uterine Cervical Neoplasms 50Precursor Cell Lymphoblastic Leukemia-Lymphoma 49Ovarian Neoplasms 47Carcinoma, Hepatocellular 46Keratosis, Actinic 44Carcinoma, Renal Cell 44Recurrence 43Head and Neck Neoplasms 43Stomach Neoplasms 38Lymphoma, Large B-Cell, Diffuse 34Urinary Bladder Neoplasms 33Squamous Cell Carcinoma of Head and Neck 32

Interventions

Lenalidomide 2Zoledronic Acid 1Vitamin D 1Dexamethasone 1Calcium Dobesilate 1Calcium 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Has results × Disease Progression × Clear all
NCT01109004 2021-12-09

BMT CTN 0702

National Heart, Lung, and Blood Institute (NHLBI)

Phase 3 Completed
758 enrolled 21 charts
Plasma cell

Hematologic Diseases, Multiple Myeloma, Disease Progression

NCT02322320 2020-05-11

Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)

National Heart, Lung, and Blood Institute (NHLBI)

Phase 3 Completed
273 enrolled 16 charts
Plasma cell

Hematologic Diseases, Multiple Myeloma, Disease Progression

NCT00171925 2012-04-11

Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I

Novartis

Phase 3 Terminated
143 enrolled 10 charts
Plasma cell

Multiple Myeloma, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡